LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

MALDI-TOF-MS Analysis Identifies Ovarian Cancer Patterns

By LabMedica International staff writers
Posted on 18 Jul 2017
Print article
Image: A scanning electron micrograph (SEM) of ovarian cancer cells (Photo courtesy of SPL).
Image: A scanning electron micrograph (SEM) of ovarian cancer cells (Photo courtesy of SPL).
Ovarian cancer (OC) is one of the leading causes of death among all gynecological malignancies and as there are no early specific symptoms, OC is diagnosed in advanced clinical stages in more than 70% cases when, despite appropriate treatment, five-year survival rate drops to 30%.

Early diagnosis improves treatment outcomes and also dramatically reduces mortality rate. However, adequate diagnostic methods are lacking and therefore novel technologies that would allow early detection of OC that are urgently needed. To broaden the knowledge on the pathological processes that occur during ovarian cancer tumorigenesis, protein-peptide profiling has been proposed.

Scientists at the Poznan University of Medical Sciences (Poznań, Poland) collected blood samples were from 89 patients operated in their Gynecologic Oncology Department on the day before surgery, between August 2014 and December 2015. Based on histopathological result the patients were divided into two groups: 44 with OC, including borderline ovarian tumors, and 45 with no pathology of the ovaries, the control group.

Serum samples were pretreated using solid-phase extraction method and eluents were mixed with a matrix solution was spotted onto the MALDI target and left to crystallize at room temperature. The Bruker Daltonics UltrafleXtreme MALDI-TOF/TOF mass spectrometer was used to perform mass spectrometry (MS) analyses in the linear positive mode. Two markers additional marker CA124 and HE4, were measured in the OC group with an electrochemiluminescence immunoassay.

A classification model with the most discriminative factors was identified using chemometric algorithms and the results were verified by external validation on an independent test set of samples. The investigators reported that the main outcome of their study was an identification of potential OC biomarkers by applying liquid chromatography coupled with tandem mass spectrometry. Application of this novel strategy enabled the identification of four potential OC serum biomarkers: complement C3, kininogen-1, inter-alpha-trypsin inhibitor heavy chain H4, and transthyretin.

The authors concluded that proteomic profiling of serum samples based on the solid phase extraction enrichment technology coupled with MALDI-TOF MS demonstrated differences in the serum protein expression in patients with OC compared with the healthy control group. The study was published on June 30, 2017, in the journal BMC Cancer.

Related Links:
Poznan University of Medical Sciences

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more